PHILADELPHIA — In patients with HF with reduced ejection fraction with or without diabetes, the SGLT2 inhibitor dapagliflozin was associated with clinically meaningful improvements in HF-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback